What Patients Should Know About Benjamin Caplan MD (2026 Doctor's Guide)
Quick Answer: Who Is Dr. Benjamin Caplan and How Does He Support Patients?
Dr. Benjamin Caplan, MD is a board-certified family physician, renowned medical cannabis pioneer, and founder of CED Clinic in Chestnut Hill, Massachusetts. Author of The Doctor-Approved Cannabis Handbook, Dr. Caplan provides in-depth medical cannabis consultations, pharmacology reviews, and personalized treatment plans for complex, treatment-resistant medical conditions.
| Benefit / Legal Protection | Massachusetts Medical Patient | Adult-Use (Recreational) Consumer |
|---|---|---|
| Dispensary Retail Taxes | 0% Total Tax (100% Tax-Free) | 20% Surcharge (Excise + Sales + Local) |
| Possession / Purchase Limit | 10 Ounces Every 60 Days | 1 Ounce Flower / 5g Concentrate / Day |
| Edibles Dosing Limit | No Milligram Cap (Clinical Potencies) | Max 5mg / Serving (100mg / Package) |
| Age Qualification | Ages 18+ Qualify Independently | Strictly 21+ Required |
Dr. Benjamin Caplan, MD is a Harvard-trained family physician and internationally recognized cannabis medicine specialist who founded CED Clinic to provide rigorous, evidence-based cannabis certifications and ongoing clinical guidance under Massachusetts law (M.G.L. c. 94I and 935 CMR 501.000). His approach integrates endocannabinoid biology, individualized chemovar selection, and compassionate patient education rather than transactional certification. Patients certified through CED Clinic gain immediate MassCIP portal access, 100% state and local tax exemption, and a personalized therapeutic protocol grounded in current 2026 clinical standards.
| Audience | Massachusetts Patients, Caregivers, Referring Clinicians & National Cannabis Medicine Seekers |
| Primary Topic | Dr. Benjamin Caplan MD: Clinical Profile, CED Clinic Services, and Massachusetts Patient Guidance |
| Legal Authority | Massachusetts Cannabis Control Commission Regulations (935 CMR 501) |
What Patients Should Know About Benjamin Caplan MD (2026 Doctor's Guide)
Patients across Massachusetts—and around the world—search for Dr. Benjamin Caplan MD because they want more than a signature on a form. They want a physician who understands the endocannabinoid system, respects the complexity of their condition, and can translate cannabis science into a practical, safe, and legal treatment plan. Here is everything you need to know before your first consultation.
- Dr. Caplan's Harvard medical training, board certifications, and the founding mission of CED Clinic as a clinical cannabis center of excellence
- How Massachusetts law (M.G.L. c. 94I and 935 CMR 501.002) enables physician discretion to certify patients with debilitating conditions beyond the enumerated list
- The endocannabinoid system biology—CB1/CB2 receptor signaling, 5-HT1A serotonergic pathways—that underpins Dr. Caplan's individualized prescribing philosophy
- The concrete financial and legal benefits of medical certification in 2026: 100% tax exemption (17–20% savings), 10-ounce 60-day rolling supply limit, and access to high-potency formulations unavailable in adult-use markets
- What a CED Clinic consultation actually involves: medical history review, chemovar guidance, MassCIP same-day registration, and ongoing clinical follow-up
- Dr. Benjamin Caplan MD is a Harvard-trained cannabis medicine specialist and founder of CED Clinic, offering rigorous, evidence-based certifications under Massachusetts law
- Massachusetts 935 CMR 501.002 grants certifying physicians broad discretion to qualify patients with debilitating conditions, enabling personalized clinical cannabis care
- CED Clinic consultations integrate endocannabinoid biology, individualized chemovar selection, and harm-reduction protocols—not transactional rubber-stamp certifications
- Certified patients receive immediate MassCIP digital access, 100% state and local tax exemption, and a 60-day rolling 10-ounce supply limit under 2026 CCC rules
| Target Question | What Patients Should Know About Benjamin Caplan MD (2026 Doctor's Guide) |
| Massachusetts Legal Basis | M.G.L. c. 94I & 935 CMR 501.000 |
| Qualifying Standard | Statutory 'Debilitating Medical Condition' determined by certifying physician with clinical discretion |
| Clinical Pharmacology | CB1/CB2 endocannabinoid receptor signaling, 5-HT1A serotonergic modulation, biphasic THC dose-response |
| Tax Exemption Benefit | 100% exempt from Massachusetts state and local cannabis excise taxes (17–20% savings for registered patients) |
| Possession Limit | 60-day rolling supply of up to 10 ounces of cannabis flower or equivalent concentrate |
| Certification Method | Physician clinical evaluation at CED Clinic followed by immediate online MassCIP portal registration and same-day temporary digital certificate |
For patients navigating chronic pain, anxiety, sleep disorders, neurological conditions, or cancer-related symptoms, the choice of certifying physician is not a bureaucratic formality—it is a clinical decision that shapes the entire therapeutic trajectory. A physician who understands the endocannabinoid system, monitors drug-drug interactions, and provides ongoing guidance produces meaningfully better outcomes than one who simply signs a form. In Massachusetts in 2026, where the adult-use market is saturated with high-potency products and marketing claims, patients deserve a physician who can cut through the noise. Dr. Caplan's profile matters because he represents a model of cannabis medicine that most patients have never encountered: evidence-grounded, pharmacologically sophisticated, and deeply patient-centered. Understanding who he is, what CED Clinic offers, and what a consultation actually involves helps patients arrive prepared, ask better questions, and leave with a therapeutic plan they can actually follow safely.
Dr. Benjamin Caplan MD is not a cannabis advocate in the political sense—he is a clinician who follows the evidence, respects the pharmacology, and takes seriously the responsibility of recommending a Schedule I substance (currently under federal rescheduling review as of 2026) to patients who are often already managing complex medical histories. His value to patients lies precisely in that rigor: the willingness to say 'this may not be right for you' as readily as 'here is how this can help.' Patients who consult Dr. Caplan at CED Clinic should expect a thorough medical conversation, not a five-minute checkbox exercise. They should expect to leave with a chemovar strategy, a dosing framework, a harm-reduction plan, and a clear understanding of their Massachusetts legal rights—including the 10-ounce 60-day supply limit, the MassCIP digital certification, and the 17–20% tax exemption that makes medical access meaningfully more affordable than the adult-use market.
Dr. Benjamin Caplan completed his medical training at Harvard Medical School and went on to practice as a board-certified family physician before founding CED Clinic—the Center for Enlightened Doctoring—in Massachusetts. His pivot toward cannabis medicine was not ideological; it was clinical. He observed patients self-medicating with cannabis for conditions that conventional pharmacology was managing poorly, and he recognized that the absence of physician guidance in that space was causing preventable harm. CED Clinic was built to fill that gap with the same rigor applied to any other specialty.
As the author of 'The Doctor-Approved Cannabis Handbook,' Dr. Caplan has synthesized thousands of patient cases, peer-reviewed literature, and endocannabinoid system research into a practical clinical framework. He has lectured internationally, consulted with regulatory bodies, and contributed to the growing body of cannabis medicine education for both patients and clinicians. In 2026, he remains one of the most cited and sought-after cannabis medicine specialists in the United States.
CED Clinic operates under full compliance with Massachusetts law—M.G.L. c. 94I and 935 CMR 501.000—and every certification issued reflects a genuine clinical evaluation, not a transactional encounter. Patients are evaluated for their specific condition, current medications, prior cannabis experience, and therapeutic goals before any certification is submitted to the Massachusetts Cannabis Control Commission's MassCIP portal.
Under 935 CMR 501.002, Massachusetts defines a 'debilitating medical condition' to include enumerated diagnoses—cancer, glaucoma, HIV/AIDS, hepatitis C, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis—but critically extends physician discretion to 'other conditions as determined in writing by a qualifying patient's healthcare provider.' This statutory flexibility is the legal engine that allows Dr. Caplan to certify patients with chronic pain, anxiety, PTSD, insomnia, and a wide range of conditions that impair daily functioning, even when those conditions are not explicitly named in the regulation.
Once a certifying physician submits the electronic certification through the MassCIP portal, patients receive a PIN immediately and can complete their free state registration online the same day. The resulting temporary digital certificate is legally valid at any Massachusetts medical dispensary. Certified patients are entitled to purchase up to 10 ounces of cannabis flower or equivalent concentrate within any rolling 60-day period—a supply limit that substantially exceeds the adult-use single-transaction limit and reflects the therapeutic quantities that chronic condition management may require.
The financial benefit is not trivial. Massachusetts imposes a combined state excise tax and local option tax on adult-use cannabis purchases that typically totals 17–20% at the point of sale. Medical patients are 100% exempt from these taxes under current CCC regulations. For a patient spending $200 per month on cannabis medicine, that exemption represents $34–$40 in monthly savings—over $400 annually—making the cost of a physician consultation recover itself within weeks.
Dr. Caplan's clinical philosophy is grounded in endocannabinoid system biology rather than anecdote. The endocannabinoid system (ECS) is a ubiquitous neuromodulatory network comprising CB1 receptors (concentrated in the brain, spinal cord, and peripheral nervous system), CB2 receptors (predominant in immune tissue and the gut), endogenous ligands including anandamide and 2-AG, and the enzymatic machinery that synthesizes and degrades them. The ECS functions as a homeostatic regulator—modulating pain signaling, inflammatory cascades, mood, appetite, sleep architecture, and stress response.
Phytocannabinoids like THC and CBD interact with this system in pharmacologically distinct ways. THC is a partial CB1 agonist, producing analgesia, appetite stimulation, and psychoactivity at therapeutic doses, but triggering tachycardia, paranoia, and anxiety at supraphysiologic doses. CBD is a negative allosteric modulator of CB1, a CB2 partial agonist, and a 5-HT1A serotonergic receptor agonist—mechanisms that collectively explain its anxiolytic, anti-inflammatory, and neuroprotective properties without psychoactivity. Understanding these distinctions is why Dr. Caplan does not simply recommend 'cannabis'; he recommends specific cannabinoid ratios, delivery methods, and dosing schedules calibrated to each patient's physiology and condition.
A consultation with Dr. Caplan is a structured clinical encounter. Patients are asked to complete a detailed intake covering their primary diagnosis, symptom burden, prior treatment history, current medications (including supplements and OTC drugs that may interact with cannabinoids via CYP450 hepatic metabolism), prior cannabis experience, and specific therapeutic goals. This is not a formality—it directly shapes the clinical recommendation. A patient on warfarin, for example, requires a very different cannabinoid protocol than a patient managing treatment-resistant insomnia with no polypharmacy concerns.
Following the evaluation, Dr. Caplan provides a personalized therapeutic framework: recommended cannabinoid ratios (e.g., 1:1 CBD:THC for daytime anxiety management, higher THC ratios for nocturnal pain), preferred delivery methods (sublingual tinctures for rapid onset and precise dosing, oral capsules for extended duration, inhalation for breakthrough symptoms), starting dose ranges, titration schedules, and clear harm-reduction guidance. The electronic certification is submitted to MassCIP immediately. Follow-up consultations are available to adjust protocols as patients gain experience and their conditions evolve.
Cannabis is not without risk, and Dr. Caplan is explicit about this with every patient. THC's biphasic dose-response curve means that the difference between therapeutic calm and acute anxiety or paranoia can be a single additional milligram. Patients with personal or family histories of psychosis, schizophrenia, or bipolar disorder require especially careful evaluation before any THC-containing protocol is initiated. Cannabis use disorder, while less common than dependence on alcohol or opioids, is a real clinical entity affecting approximately 9% of users—a figure that rises with early-onset use and high-frequency consumption.
The practical harm-reduction framework Dr. Caplan applies is consistent: start at the lowest effective dose, titrate slowly over days to weeks rather than hours, keep a CBD-rich product on hand as a pharmacological counterweight to THC-induced anxiety, avoid high-potency concentrates and distillates until tolerance and individual response are well characterized, and never combine cannabis with alcohol or benzodiazepines without explicit clinical guidance. These are not disclaimers—they are the clinical guardrails that separate therapeutic cannabis use from recreational overconsumption.
The evidence base supporting clinical cannabis medicine in 2026 is substantially stronger than it was a decade ago, though it remains uneven across conditions and formulations. For chronic pain, the evidence is most robust: multiple systematic reviews and meta-analyses, including those published in JAMA and The Lancet, support cannabinoids as effective adjuncts for neuropathic and inflammatory pain when conventional therapies are inadequate. For anxiety, the evidence is promising but more heterogeneous—CBD's anxiolytic properties are supported by randomized controlled trials in social anxiety disorder and preclinical models of generalized anxiety, while THC's anxiogenic potential at high doses is well-documented. For sleep, insomnia, PTSD, and appetite dysregulation in oncology patients, the clinical evidence ranges from moderate to strong depending on the specific outcome measure. Dr. Caplan's clinical approach is calibrated to this evidence gradient: he is more confident in cannabinoid recommendations for conditions with stronger evidence bases and more cautious—and more explicit about uncertainty—where the literature is thinner.
Legitimate skepticism about cannabis medicine in 2026 centers on several real concerns. The certification industry in Massachusetts, as in other legal states, has attracted practitioners who offer rapid-fire, high-volume certifications with minimal clinical evaluation—a practice that undermines patient safety and the credibility of cannabis medicine as a specialty. Dispensary marketing frequently overstates the evidence for specific products, terpene profiles, and strain-specific effects in ways that are not supported by peer-reviewed literature. The placebo effect in subjective symptom conditions like anxiety and pain is substantial and must be accounted for in any honest clinical assessment. And the absence of large-scale, FDA-grade randomized controlled trials for whole-plant cannabis flower—a direct consequence of Schedule I federal restrictions that are only now beginning to ease—means that many clinical recommendations rest on observational data, patient-reported outcomes, and mechanistic plausibility rather than the gold-standard evidence that governs conventional pharmacotherapy. Dr. Caplan acknowledges these limitations openly, which is precisely what distinguishes rigorous cannabis medicine from advocacy.
A Massachusetts medical cannabis certification from Dr. Caplan or any other physician is not a prescription for a cure. It is a clinical authorization to access a therapeutic tool that, used correctly and under ongoing medical supervision, may meaningfully improve quality of life for patients with debilitating conditions. It does not replace emergency psychiatric care for acute suicidality or psychosis. It does not substitute for disease-modifying therapies in conditions like multiple sclerosis or cancer. It does not guarantee symptom relief—individual response to cannabinoids varies substantially based on genetics, endocannabinoid tone, prior exposure, and the specific formulation used. And it does not confer federal legal protection: cannabis remains a controlled substance under federal law as of 2026, with rescheduling to Schedule III under active DEA and HHS review but not yet finalized. Patients in federally subsidized housing, federal employment, or safety-sensitive transportation roles must understand these boundaries before pursuing certification.
Cannabis medicine does not exist in a clinical vacuum. The patients who consult Dr. Caplan are typically not cannabis novices seeking a legal workaround—they are people who have often exhausted or partially exhausted conventional treatment options, who are managing complex symptom burdens, and who are looking for a physician willing to engage seriously with a therapeutic modality that mainstream medicine has historically dismissed. The integrative medicine movement has increasingly recognized cannabis as one tool within a broader toolkit that includes nutrition, sleep optimization, mindfulness-based stress reduction, physical therapy, and psychotherapy.
The tension between patient self-medication and guided medical treatment is clinically significant. A substantial proportion of Massachusetts adults who use cannabis for therapeutic purposes do so without any physician involvement—purchasing from adult-use dispensaries, relying on budtender recommendations, and titrating by trial and error. This is not inherently dangerous for every patient, but it systematically excludes the clinical safeguards—drug interaction screening, dose guidance, contraindication assessment—that can make the difference between benefit and harm, particularly for patients on complex medication regimens or with psychiatric comorbidities.
The most durable therapeutic outcomes Dr. Caplan observes in his practice are not produced by cannabis alone. They emerge when cannabis is integrated into a broader lifestyle and treatment framework: consistent sleep schedules, regular physical activity, dietary anti-inflammatory practices, and—where indicated—concurrent psychotherapy or psychiatric care. Cannabis can reduce the symptom burden that makes these other interventions feel impossible to sustain. That is its most powerful clinical role: not as a replacement for comprehensive care, but as a facilitator of it.
I have now conducted tens of thousands of cannabis medicine consultations, and the question I am asked most often is some version of: 'Is this going to work for me?' My honest answer is always the same: I don't know yet, and anyone who tells you they do is overpromising. What I can tell you is that we are going to approach this systematically—starting with your biology, your history, your goals, and the best available evidence—and we are going to adjust based on what we actually observe in you, not what worked for someone else.
The patients who do best with cannabis medicine are not the ones who come in expecting a miracle. They are the ones who come in willing to be methodical—to start low, to track their symptoms honestly, to communicate with me when something isn't working, and to understand that finding the right therapeutic window sometimes takes weeks of careful titration. That process is not a failure of the medicine; it is the medicine working as it should. Cannabinoid pharmacology is genuinely individualized in ways that most conventional drugs are not, and that individualization requires patience and clinical partnership.
What I want every patient to understand before they walk through our door is that I take this seriously. I take your condition seriously, I take the pharmacology seriously, and I take the legal and safety framework seriously. Massachusetts has built one of the most thoughtful medical cannabis regulatory structures in the country, and my job is to help you navigate it in a way that is safe, legal, evidence-informed, and genuinely therapeutic. That is what CED Clinic is for.
For the patient who is cautious by nature—who wants to understand before they commit, who has been burned by overpromising clinicians or underwhelming treatments before—Dr. Caplan's approach is designed specifically for you. The rigor is the point. The clinical evaluation, the personalized protocol, the harm-reduction framework, the ongoing follow-up: these are not upsells. They are the infrastructure of responsible cannabis medicine. Come with your questions, your skepticism, and your medical records. Leave with a plan you actually understand.
Dr. Benjamin Caplan MD Through Eight Critical Lenses
Patients, clinicians, regulators, skeptics, historians, and caregivers each evaluate a cannabis medicine specialist differently. These eight perspectives examine Dr. Caplan's practice, credentials, and clinical approach from every meaningful angle.
Patient Takeaway
If you are a Massachusetts patient considering a consultation with Dr. Caplan, the most important thing to know is that you will not be rushed. You will be asked real questions about your health, your medications, and your goals. You will leave with a specific plan—not a vague suggestion to 'try some CBD'—and you will have immediate legal access to medical dispensaries at 17–20% less than adult-use prices. The 10-ounce 60-day supply limit under 2026 CCC rules gives you meaningful therapeutic flexibility that the adult-use market simply does not provide.
Bring your skepticism. Bring your questions. Bring your prior medical records if you have them. Dr. Caplan's consultations are most productive when patients arrive as active participants rather than passive recipients.
Clinician's Perspective
From a clinical standpoint, Dr. Caplan's practice model addresses a genuine gap in the healthcare system. Most primary care physicians lack the training, time, or institutional support to engage substantively with cannabis medicine—leaving patients to navigate a complex pharmacological landscape without guidance. A specialist who can evaluate endocannabinoid tone, assess CYP450 drug interaction risk (particularly relevant for patients on anticoagulants, antiepileptics, or immunosuppressants), and provide structured titration protocols fills a real clinical need.
The CB1/CB2 receptor pharmacology and 5-HT1A serotonergic modulation that underpin cannabinoid therapeutics are not trivial. THC's partial CB1 agonism produces dose-dependent effects that can shift from anxiolytic to anxiogenic within a narrow concentration range. CBD's negative allosteric modulation of CB1 and its 5-HT1A agonism create a pharmacological profile that is genuinely distinct from THC and clinically useful in conditions where psychoactivity is undesirable. A physician who understands these distinctions can make recommendations that a budtender, however well-intentioned, cannot.
Referring clinicians should know that Dr. Caplan's practice includes communication back to primary care teams when patients consent to this. Cannabis medicine does not exist in isolation from the rest of a patient's care, and coordination with prescribing physicians—particularly around opioid tapering, benzodiazepine reduction, and sleep medication management—is a clinical priority at CED Clinic.
A Skeptical Read
A reasonable skeptic will note that the cannabis medicine specialty, including CED Clinic, operates in a commercial environment where the physician's revenue depends on certifications. This creates an inherent conflict of interest that does not exist in the same form in conventional specialty medicine. Patients should ask: how often does Dr. Caplan decline to certify a patient? What are his explicit contraindications? A practice that certifies every patient who walks through the door is not practicing medicine—it is practicing commerce.
The evidence base for many of the conditions Dr. Caplan certifies remains observational and patient-reported rather than derived from large randomized controlled trials. While the mechanistic rationale for cannabinoid therapeutics is scientifically sound, the clinical translation—which specific product, at which dose, for which patient, with which outcome—is still more art than evidence-based science for many conditions. Patients deserve to hear this acknowledged explicitly, not buried in enthusiasm for the endocannabinoid system.
Regulatory & Legal Analysis
Massachusetts 935 CMR 501.002's broad physician discretion clause is both the program's greatest strength and its most significant regulatory vulnerability. It enables genuinely compassionate, individualized care for patients with conditions that do not fit neatly into enumerated diagnostic categories. It also creates the conditions for low-effort, high-volume certification mills that technically comply with the statute while providing no meaningful clinical service. The CCC's oversight of certifying physicians—including the requirement that physicians have a bona fide patient-provider relationship and conduct a full assessment—is the regulatory guardrail, but enforcement has historically been inconsistent.
The medical versus adult-use market distinction in Massachusetts is increasingly strained. As adult-use product quality and variety have expanded, the medical market's unique value proposition has narrowed to tax exemption, supply limits, and physician guidance. For patients who do not need or want clinical oversight, the adult-use market is functionally equivalent. The CCC's 2026 regulatory framework has not yet resolved this tension, and the long-term viability of a robust medical program depends on whether physician-guided cannabis care can demonstrate measurably better patient outcomes than self-directed adult-use consumption.
Municipal zoning restrictions and host community agreement requirements continue to limit dispensary access in many Massachusetts communities, disproportionately affecting patients in rural and lower-income areas who may lack transportation to urban dispensary clusters. This geographic inequity is a structural problem that physician certification alone cannot solve.
The CCC's social equity program, designed to address the disproportionate impact of cannabis prohibition on communities of color, has faced implementation challenges that persist into 2026. Patients from equity-eligible communities should be aware of fee waivers and priority licensing provisions that may affect dispensary availability in their area.
Comparative State & Historical Context
Massachusetts voters approved medical cannabis through Ballot Question 3 in November 2012, establishing one of the earlier state medical programs on the East Coast. The program launched slowly—the first dispensaries did not open until 2015—but has matured significantly. The 2016 adult-use legalization vote (Question 4) and the subsequent 2018 launch of recreational sales fundamentally changed the landscape, creating the dual-market structure that defines Massachusetts cannabis access in 2026. Dr. Caplan's practice has evolved alongside this regulatory history, adapting to each successive CCC rulemaking cycle.
Compared to states like Idaho or Kansas, which maintain complete prohibition, Massachusetts patients enjoy extraordinary access. Compared to states like California or Oregon, where physician oversight requirements are minimal and the medical program has largely collapsed into the adult-use market, Massachusetts has maintained a more clinically meaningful medical program. The physician discretion standard, the tax exemption, and the higher supply limits collectively create genuine incentives for patients with serious conditions to seek medical certification rather than simply purchasing from adult-use dispensaries.
Dispensary Realities & Budget
The 17–20% tax exemption is the most immediately tangible benefit of medical certification for most patients. At current Massachusetts dispensary price points—where a gram of flower ranges from $8 to $18 and a 30-count edible package runs $25 to $50—the tax savings compound quickly. A patient spending $150 per month on cannabis medicine saves $25–$30 monthly, recovering the cost of a physician consultation within two to three months and generating net savings every month thereafter.
Medical dispensary menus in Massachusetts in 2026 include formulations not available in adult-use stores: high-dose edibles exceeding the 5mg-per-piece adult-use limit, pharmaceutical-grade tinctures with precise cannabinoid ratios, and concentrated oral formulations designed for patients with severe pain or appetite dysregulation. These products are clinically meaningful for patients who require consistent, high-dose cannabinoid delivery that the adult-use market cannot legally provide.
Patients should approach dispensary visits with Dr. Caplan's protocol in hand rather than relying solely on budtender recommendations. Budtenders are not clinicians, and their product suggestions—however well-intentioned—are not calibrated to your specific medical history, medications, or therapeutic goals. The Certificate of Analysis (COA) for any product should be reviewed for cannabinoid potency, terpene profile, and residual solvent testing before purchase.
Federal Rescheduling & Research
The most consequential development on the horizon for cannabis medicine in 2026 is the ongoing federal rescheduling process. The DEA and HHS recommendation to move cannabis from Schedule I to Schedule III—initiated in 2024 and still working through administrative and legal review as of 2026—would not legalize cannabis federally, but it would remove the Schedule I research barrier that has constrained clinical trial design for decades. Schedule III status would enable pharmaceutical-grade clinical trials, facilitate insurance reimbursement discussions, and allow cannabis-derived medications to move through the FDA approval pathway more readily. Minor cannabinoids including CBG (cannabigerol), CBN (cannabinol), and THCV (tetrahydrocannabivarin) are attracting increasing research attention for their distinct receptor pharmacology and potential therapeutic profiles in inflammation, sleep, and metabolic regulation. Dr. Caplan's clinical protocols are already incorporating these emerging cannabinoids where evidence supports their use, positioning CED Clinic patients to benefit from the next generation of cannabinoid therapeut
💬 Join the Conversation
Have questions about qualifying for a medical marijuana card in Massachusetts? Ask Dr. Caplan →
Want to connect with other patients and discuss local dispensary options? Join the CED Clinic patient community forum →